Last reviewed · How we verify
Peptides
Peptides is a Biologic drug developed by H. Lee Moffitt Cancer Center and Research Institute. It is currently FDA-approved. Also known as: NSC 717388, NSC 683473, NSC 737063, NeoAntigen peptides.
At a glance
| Generic name | Peptides |
|---|---|
| Also known as | NSC 717388, NSC 683473, NSC 737063, NeoAntigen peptides, Personalized peptides |
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer (PHASE2)
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PHASE3)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- DDAVP for Pituitary Adenoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Peptides CI brief — competitive landscape report
- Peptides updates RSS · CI watch RSS
- H. Lee Moffitt Cancer Center and Research Institute portfolio CI
Frequently asked questions about Peptides
What is Peptides?
Peptides is a Biologic drug developed by H. Lee Moffitt Cancer Center and Research Institute.
Who makes Peptides?
Peptides is developed and marketed by H. Lee Moffitt Cancer Center and Research Institute (see full H. Lee Moffitt Cancer Center and Research Institute pipeline at /company/h-lee-moffitt-cancer-center-and-research-institute).
Is Peptides also known as anything else?
Peptides is also known as NSC 717388, NSC 683473, NSC 737063, NeoAntigen peptides, Personalized peptides.
What development phase is Peptides in?
Peptides is FDA-approved (marketed).
Related
- Manufacturer: H. Lee Moffitt Cancer Center and Research Institute — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: NSC 717388, NSC 683473, NSC 737063, NeoAntigen peptides, Personalized peptides
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing